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Mastitis is a substantial clinical problem in lactating
women that may result in severe pain and abrupt
termination of breastfeeding, thereby predisposing
infants to long-term health risks. Many cases of mas-
titis involve no known infectious agent and may fun-
damentally be due to autoimmune-mediated inflam-
mation of the breast. Herein, we develop a murine
model of autoimmune mastitis and provide a detailed
characterization of its resulting phenotype of breast
failure and lactation insufficiency. To generate breast-
specific autoimmunity, we immunized SWXJ mice
with recombinant mouse -lactalbumin, a lactation-
dependent, breast-specific differentiation protein
critical for production of lactose. Mice immunized
with -lactalbumin showed extensive T-cell–mediated
inflammation in lactating normal breast parenchyma
but none in nonlactating normal breast parenchyma.
This targeted autoimmune attack resulted in breast
failure characterized by lactation insufficiency and
decreased ability to nurture offspring. Although im-
munization with -lactalbumin had no effect on fer-
tility and birth numbers, pups nursed by -lactalbu-
min–immunized mice showed significantly disrupted
growth often accompanied by kwashiorkor-like nutri-
tional abnormalities, including alopecia, liver toxic-
ity, and runting. This experimental model of autoim-
mune breast failure has useful applications for
prophylactic breast cancer vaccination and for ad-
dressing inflammatory complications during breast-
feeding. In addition, this model is suited for investi-gating nutritionally based “failure-to-thrive” issues,
particularly regarding the long-term implications of
postnatal nutritional deprivation. (Am J Pathol 2012,
181:775–784; http://dx.doi.org/10.1016/j.ajpath.2012.05.025)
Mastitis is an inflammation of the breast that often causes
women to stop breastfeeding. It is clinically characterized
by breast engorgement, formation of noncaseating gran-
ulomatous inflammation with leukocytic infiltrates, and
blocked milk ducts. If left untreated, mastitis can lead to
lactation failure, recurrent inflammation, or breast ab-
scess.1 Mastitis has been traditionally viewed to affect
less than 3% of American women in their childbearing
years.2 However, several studies indicate that mastitis
may be much more prevalent, perhaps affecting up to
33% of lactating women.3–6
Mastitis has been predominantly associated with
Staphylococcus aureus infections.7,8 Several other etio-
pathogenic factors have also been implicated, including
the use of illicit drugs, stress during labor, and trauma to
the breast, all of which may cause or predispose to in-
flammation and related abnormalities.9 Also, some cases
of mastitis seem to involve no known infectious or other
causative agent and, as such, suggest that breast-spe-
cific autoimmunity may be implicated. Indeed, idio-
pathic granulomatous mastitis is one form of this dis-
order that is often responsive to glucocorticoid
treatment10–13 and has been attributed to a localized
immune response to an unidentified breast-specific
antigen.14
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trophilic and lymphocytic infiltration involving T and B
cells.15,16 Immunohistochemical analyses of breast infil-
trates often show a predominance of T cells17,18 but may
also show dense intralobular, perilobular, and perivascular
B-cell infiltrates with lobular atrophy and sclerosis.19 How-
ever, breast inflammation in the absence of any infectious
pathogens or other contributing factors distinguishes idio-
pathic mastitis and a putative autoimmune etiology.
In the present study, we define the detailed phenotype
of breast failure by creating a murine experimental auto-
immune mastitis. We selected mouse -lactalbumin as
the target antigen to induce autoimmune disruption of
breast function because it is a differentiation protein in-
volved in regulation of lactose biosynthesis and because its
expression is breast specific and lactation dependent.20–23
We found that immunization of SWXJmice with recombinant
mouse -lactalbumin causes extensive T-cell–mediated in-
flammation in lactating normal breast parenchyma and
none in nonlactating normal breast parenchyma. This tar-
geted autoimmune attack results in breast failure charac-
terized by lactation insufficiency and decreased ability to
nurture offspring. Although we observed no effect on fertil-
ity, pups nursed by -lactalbumin–immunized mice consis-
tently showed significant growth inhibition, often compli-
cated by kwashiorkor-like nutritional abnormalities and
runting. This experimental model has useful applications for
prophylactic breast cancer vaccination, for addressing in-
flammatory complications during breastfeeding, and for in-
vestigating nutritionally based “failure-to-thrive” issues, par-
ticularly regarding the long-term implications of nutritional
Table 1. Primer Pairs for Quantitative RT-PCR, Cloning of -Lact
Protein Sequ
Quantitativ
IFN-
Forward 5=-TCAAGTGGCATAG
Reverse 5=-TGGCTCTGCAGGA
IL-10
Forward 5=-GGTTGCCAAGCCT
Reverse 5=-ACCTGCTCCACTG
-Casein
Forward 5=-AAGTTTCCCCAGC
Reverse 5=-CCAAAGGGGAAAG
-Lactalbumin
Forward 5=-TCAACGACAACGG
Reverse 5=-CACAGGGGCAGGA
GAPDH
Forward 5=-TTCACCACCATGG
Reverse 5=-GGCATCGACTGTC
Cloning of -
-Lactalbumin
Forward 5=-TTCGTTCCTTTGT
Reverse 5=-GTCCTCTAGAGTC
Convention
IFN-
Forward 5=-TGATGGCCTGATT
Reverse 5=-GGATATCTGGAGG
-Actin
Forward 5=-CAGGGTGTGATGG
Reverse 5=-GCAGGATGGCGTG
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.deprivation during the early stages of development.Materials and Methods
Production of Recombinant Mouse
-Lactalbumin
mRNA was extracted (Qiagen Inc., Valencia, CA) from
lactating mouse mammary tissue taken from 8-week-old
female SWXJ mice, and -lactalbumin cDNA was gener-
ated by RT-PCR using -lactalbumin–specific primers
(Table 1). The cDNA for mouse -lactalbumin was in-
serted into the pQE-82L expression vector (Qiagen Inc.)
for producing a 6X-His–tagged fusion protein. SG13009
Escherichia coli (Qiagen Inc.) was transformed and
screened for expression with horseradish peroxidase–
conjugated His antibody (Qiagen Inc.). High-level ex-
pression colonies were selected after induction with iso-
propyl thiogalactopyronidase and treatment with His
antibody. Plasmids from selected colonies were purified
using the Plasmid Maxi Kit (Qiagen Inc.) and sequenced
for verifying proper orientation and alignment. His-tagged
-lactalbumin was purified under denaturing conditions
using a nickel-nitrilo triacetic acid affinity chromatogra-
phy column (Qiagen Inc.). The column was washed, and
multiple elution fractions were collected and electropho-
resed on 15% Tris-HCl SDS-PAGE denaturing gels with
Kaleidoscope prestained molecular weight markers (Bio-
Rad Laboratories, Hercules, CA). The gels were blotted
onto Immobilon-P polyvinylidene difluoride membrane
(Millipore, Bedford, MA), blocked with 3% bovine serum
albumin, and stained using polyclonal goat anti-mouse
-lactalbumin primary antibody (Santa Cruz Biotechnol-
n, and Conventional RT-PCR
Amplicon length (bp)
CR
GAAGAA-3= 192
ATG-3=
GA-3= 190
CT-3=
AATCT-3= 248
ATACT-3=
CAGAGT-3= 292
AAGGAC-3=
GGC-3= 236
3=
umin
GTGTG-3= 581
GTGTC-3=
CR
TCAA-3= 110
GCAA-3=
ATGG-3= 409
GAGC-3=albumi
ence
e RT-P
ATGTG
TTTTC
TATCG
CCTTG
ACAGC
GCATC
CAGCA
GCAGC
AGAAG
ATGA-
Lactalb
TCCTG
CGGTG
al RT-P
GTCTT
AACTG
TGGGA
AGGGAogy, Santa Cruz, CA) and horseradish peroxidase–la-
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Cruz Biotechnology). Detection was performed using
ECL chemiluminescence reagents (GE Healthcare,
Buckinghamshire, UK) and HyBlot autoradiography film
(Denville Scientific, Metuchen, NJ). Before immunization
or use in cultures, His-tagged -lactalbumin was further
purified by reverse-phase high-performance liquid chro-
matography to yield endotoxin-free protein.24
Mice and Immunization
SWXJ (H-2q,s) mice were generated by mating SJL/J
(H-2s) males with SWR/J (H-2q) females (The Jackson
Laboratory, Bar Harbor, ME). At 8 to 10 weeks of age,
mice were injected s.c. in the abdominal flank with 150
g of recombinant mouse -lactalbumin in 200 L of
emulsion of equal volumes of water and complete
Freund’s adjuvant (CFA) containing 400 g of Mycobac-
teria tuberculosis H37RA (Difco, Detroit, MI). Control mice
were immunized with CFA alone. All the protocols were
approved by the Institutional Animal Care and Use Com-
mittee of the Cleveland Clinic and were performed in
compliance with the Public Health Service policy on hu-
mane care and use of laboratory animals.
Phenotype of Autoimmune-Induced Breast
Failure
To determine the phenotype of autoimmune-induced
breast failure, -lactalbumin–immunized female SWXJ
mice and control female mice immunized with CFA alone
were mated serially with the same SWXJ male partners
over several mating periods. All the litters were weighed
daily until weaning at 3 weeks of age.
Proliferation Assays
To determine the immunogenicity of recombinant mouse
-lactalbumin, female SWXJ mice were immunized with
150 g of protein, and 10-day primed inguinal and axil-
lary lymph node cells (LNCs) were teased into single cell
suspensions, washed thoroughly in HBSS (Life Technol-
ogies, Grand Island, NY), and plated at 3  105 cells per
microititer well in 96-well flat-bottomed Falcon plates (BD,
Franklin Lakes, NJ) in Dulbecco’s modified Eagle’s me-
dium (Mediatech Cellgro, Herndon, VA) supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT), 2
mmol/L fresh L-glutamine, 100 U/mL of penicillin, 100
g/mL of streptomycin, and 30 mmol/L HEPES buffer
(Invitrogen, Carlsbad, CA) at a final volume of 200 L per
well. Recombinant -lactalbumin was added in serial 10-
fold dilutions to triplicate wells, with positive control wells
containing 2 g/mL of anti-mouse CD3 (BD Biosciences,
San Jose, CA) and negative control wells containing no
antigen. After 72 hours of culture, each well was pulsed
with [methyl-3H]thymidine (l.0 Ci per well; specific ac-
tivity, 6.7 Ci/mmol; New England Nuclear, Boston, MA)
and harvested 16 hours later by aspiration onto glass fiber
filters (Tomtec Inc., Hamden, CT). Levels of incorporated
radioactivity were determined by scintillation spectrometry.Results are expressed as mean counts per minute of ex-
perimental cultures with antigen divided by mean counts
per minute of cultures without antigen (stimulation index).
ELISA
Cytokine concentrations were determined by enzyme-
linked immunosorbent assay (ELISA) measurement of su-
pernatants of 10-day primed lymphocytes cultured in
supplemented Dulbecco’s modified Eagle’s medium for
48 hours at a concentration of 5  106 cells per well in
24-well flat-bottomed Falcon plates (BD) in the presence
of 20 g/mL of antigen in a final volume of 2.0 mL per
well. Purified capture/detection antibody pairs and re-
combinant cytokines were obtained commercially (BD
Biosciences) and included anti-mouse interferon-gamma
(IFN-; R4-6A2 and biotin XMG 1.2), anti-mouse IL-2
(JES6-1A12 and biotin JES6-5H4), anti-mouse IL-5
(TRFK5 and biotin TRFK4), and anti-mouse IL-10 (JES5-
2A5 and biotin SXC-1). Absorbance was measured at
405 nm using a model 550 enzyme-linked immunosor-
bent assay microplate reader (Bio-Rad Laboratories).
Standard values were plotted as absorbance versus cy-
tokine concentration, and sample cytokine concentra-
tions were determined as values in the linear part of the
standard curve established using known concentrations
of each cytokine.
Real-Time qRT-PCR
Eight weeks after immunization with -lactalbumin or CFA
alone, total RNA was extracted from lactating mammary
tissue using the RNeasy mini kit (Qiagen Inc.). cDNA was
synthesized using reverse transcription mix (RETRO-
script for RT-PCR; Ambion, Austin, TX) containing 2 L of
oligo dT primers, 1 mmol/L dNTPs, 100 IU of Moloney
murine leukemia virus reverse transcriptase, and 10 IU of
RNase inhibitor. The reaction mixture was heated to 42°C
for 60 minutes followed by heat inactivation at 95°C for 5
minutes. Quantitative real-time RT-PCR (qRT-PCR) was
performed using primer pairs for murine IFN-, IL-10,
-casein, -lactalbumin, and glyceraldehyde-3-phos-
phate dehydrogenase (Table 1). cDNAs were assayed
separately in 96-well plates (Applied Biosystems, Foster
City, CA) in 25 L of reaction volume containing 1XSYBR
Green PCR buffer, 3 mmol/L MgCl2, 1 mmol/L dNTPs,
0.01 IU/L of AmpErase uracil N-glycosylase, and 0.025
IU/L of AmpliTaq Gold DNA polymerase (Applied Bio-
systems). Samples were amplified in an automated fluo-
rometer (ABI Prism 7700 sequence detection system;
Applied Biosystems), and transcripts were calculated ac-
cording to the comparative threshold cycle method using
glyceraldehyde-3-phosphate dehydrogenase transcripts
as endogenous controls. The data are represented as
relative gene expression, defined as the ratio of test gene
expression to glyceraldehyde-3-phosphate dehydroge-
nase gene expression for each tissue analyzed. Conven-
tional RT-PCR was performed using IFN-–specific prim-
ers, with -actin primers as amplification controls (Table
1). All the RT-PCR reactions were performed in 25 L of
volume using 1X PCR buffer, 3 mmol/L MgCl2, 1 mmol/L
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AJP September 2012, Vol. 181, No. 3dNTPs, and 0.025 IU/L of AmpliTaq DNA polymerase.
Amplified products were electrophoresed on a 1.5% aga-
rose gel and were stained with ethidium bromide, and
amplicons were recorded on a UV transilluminator using
a gel documentation system (Bio-Rad Laboratories).
Liver Enzyme Analysis
Concentrations of serum glutamic oxaloacetic transami-
nase (aka aspartate aminotransferase) and serum glu-
tamic pyruvic transaminase (aka alanine aminotransfer-
ase) were determined by the UV-kinetic spectrometry
method using alanine aminotransferase/glutamic pyruvic
transaminase and aspartate aminotransferase/glutamic
oxaloacetic transaminaseassay kits (Teco Diagnostics,
Anaheim, CA).
T-Cell Purification
Ten days after immunization with recombinant mouse
-lactalbumin, CD4 and CD8 T cells were positively
purified from whole LNCs by magnetic bead separation
using a MidiMACS cell separator (Miltenyi Biotec Inc.,
Auburn, CA). Purities of enriched fractions were deter-
mined by flow cytometry analysis using CellQuest software
version 3.3 (BD Biosciences) and were consistently found
to be 90%.
Immunohistochemical Analysis
Mouse mammary glands were fixed in 10% phosphate-
buffered formalin (Fisher Scientific, Fair Lawn, NJ) and
embedded in paraffin. Sections (10 m) were sequen-
tially unmasked in 1 mmol/L EDTA (pH 8.0), blocked with
5% normal goat serum (Vector Laboratories, Burlingame,
CA), incubated with a 1:50 dilution of rat anti-mouse CD3
(Novacastra, Newcastle, UK), incubated with 1:100 dilu-
tion of mouse-adsorbed biotinylated goat anti-rat IgG (BD
Biosciences), treated with 1.5% H2O2 in methanol, and de-
veloped by sequential treatment with streptavidin–horse-
radish peroxidase complex (ABC kit; Vector Laboratories),
diaminobenzidine, and H2O2 substrate (BioGenex, San Ra-
mon, CA). Slides were counterstained with hematoxylin 2
(Richard-Allan Scientific, Kalamazoo, MI), dehydrated in an
ascending gradient of ethanol followed by xylene, and
mounted in Cytoseal 60 (Stephens Scientific, Riverdale, NJ)
for examination under light microscopy.
Passive Transfer of Autoimmune-Induced
Breast Failure
SWXJ female mice were immunized with either 150 g of
-lactalbumin in CFA or 150 g of recombinant human
cochlin as an irrelevant control antigen. Ten days after
immunization, LNCs were activated for 4 days with 20
g/mL of recombinant mouse -lactalbumin, and 2 to 3
107 cells were injected i.p. into naive lactating female
SWXJ recipients. In addition, CD4 T cells and CD8 T
cells were positively selected from antigen-activated LNC
cultures by magnetic bead separation as described pre-viously herein and injected i.p. into naive lactating female
recipients at 2 to 3  107 cells per mouse. Four weeks
after each transfer, RNA was isolated from lactating
mammary glands and was analyzed by qRT-PCR for
gene expression as described previously herein using
primer pairs for murine -casein and glyceraldehyde-3-
phosphate dehydrogenase (Table 1).
Biostatistical Analysis
Significance between levels of mRNA expression and
serum liver enzymes was determined by the t-test. Sig-
nificance between pup growth curves was determined by
one-way analysis of variance.
Results
-Lactalbumin Immunization Induces a
Proinflammatory Type-1 Immune Response
We selected -lactalbumin as the target autoantigen be-
cause it is a lactation-dependent differentiation protein
expressed exclusively and at high levels in lactating
mammary epithelial cells but not in nonlactating breast
tissues.20–23 -Lactalbumin cDNA was generated by re-
verse transcription of RNA extracted from lactating
mouse breast tissue and inserted into an E. coli expres-
sion vector for producing recombinant fusion proteins
with N-terminal 6X-His tag. Production of 6X-His–tagged
-lactalbumin in E. coli was induced by adding 1 mmol/L
isopropyl thiogalactopyronidase to cultures in log phase
and purified by nickel-nitrilo triacetic acid affinity chroma-
tography involving serial acidic elutions (Figure 1A). The
molecular weight of -lactalbumin was determined by gel
electrophoresis using Kaleidoscope prestained protein
standards, and the protein was further purified before use
by reverse-phase high-performance liquid chromatogra-
phy to yield an endotoxin-free product.24
Ten days after immunization of female SWXJ mice with
recombinant mouse -lactalbumin, LNCs showed dose-
dependent proliferation in recall responses to -lactalbu-
min and were unresponsive to recombinant human co-
chlin generated in E. coli in a virtually identical manner
(Figure 1B).25 Responsiveness to -lactalbumin involved
cytokine production consistent with a proinflammatory
type-1 response with high production of IFN- and IL-2
and low production of IL-5 and IL-10 (Figure 1C). Re-
sponsiveness to -lactalbumin involved CD4 and CD8
T cells, as shown by magnetic bead separation of puri-
fied populations from LNCs 10 days after immunization
(Figure 1D).
-Lactalbumin Immunization Causes Infiltration
of CD3 T Cells in Lactating Breast Tissue Only
We next examined histologic changes associated with
-lactalbumin immunization. Lactating and nonlactating
SWXJ female mice were immunized with -lactalbumin in
CFA or with CFA alone, and breast tissues were exam-
ined 6 to 7 weeks after immunization. Immunohistochem-
okines I
Cs 10 d
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CD3 T cells in breast tissues from lactating mice immu-
nized with -lactalbumin but not from control lactating mice
immunized with CFA alone or from nonlactating mice immu-
nized with either -lactalbumin or CFA (Figure 2).
Altered Gene Expression in Lactating Breast
Tissues From -Lactalbumin–Immunized Mice
We next assessed molecular changes occurring in lac-
tating breast tissues from mice immunized with -lactal-
bumin. Six weeks after immunization with either -lactal-
bumin or CFA alone, RNA from lactating mammary tissue
was analyzed for gene expression by real-time qRT-PCR.
We found that lactating breast tissue from -lactalbumin–
Figure 1. -Lactalbumin immunization induces a proinflammatory type-1 im
Arrows show the positions of the -lactalbumin monomer and dimer. Posi
female mice were immunized with 150 g of recombinant mouse -lactalb
responses over a broad dose range to -lactalbumin but not to recombinan
manner. C: ELISA of culture supernatants from 10-day LNCs stimulated w
cytokines IFN- and IL-2 with minimal production of the type 2 regulatory cyt
from CD4 and CD8 T cells purified by magnetic bead separation from LN
Figure 2. -Lactalbumin immunization causes infiltration of CD3 T cells in
lactating breast tissue only. Immunohistochemical analysis shows numerous
CD3 T cells clustered in periductal areas (arrows) of breast tissues from
lactating mice immunized with -lactalbumin 6 to 7 weeks before initiation
of lactation (top left panel). Clusters of CD3 T cells were not observed in
breast tissues from lactating mice immunized with CFA (top right panel) or
in nonlactating mice immunized with either -lactalbumin (bottom left
panel) or CFA (bottom right panel). Scale bars: 50 m.immunized mice showed significantly elevated gene ex-
pression levels of IFN- (P  0.001) but not IL-10 (P 
0.10), indicating the induction of a type 1 proinflammatory
T-cell response (Figure 3A). In addition, we found signif-
icantly increased gene expression of the breast-specific,
lactation-dependent differentiation proteins -lactalbu-
min (P  0.002) and -casein (P  0.0008), indicating a
compensatory homeostatic response of the breast tissue
to produce more milk in the presence of an autoimmune
attack. Enhanced expression of these lactation genes did
not occur in nonlactating breast tissue from mice immu-
nized with either -lactalbumin or CFA (Figure 3B). Thus,
enhanced expression of these lactation proteins serves
as a surrogate marker for detecting breast failure. It is
important to note that 6 weeks after immunization of non-
lactating female mice with -lactalbumin, we did not ob-
serve any measurable increase in gene expression levels
of IFN-, a cytokine whose expression is closely linked to
the presence of activated proinflammatory type-1 T cells
(Figure 3C). Thus, -lactalbumin autoimmune inflamma-
tion is normally confined to the lactating breast and
spares all other normal tissues.
Functional Phenotype of Autoimmune Breast
Failure
Since we observed inflammation in lactating breast tissue
only, we hypothesized that -lactalbumin–immunized
mice may manifest lactation abnormalities that affect pup
growth. Thus, 4 weeks after immunization with either
-lactalbumin or CFA alone, females were mated with the
same males for the same period, and litters were exam-
ined daily for 3 weeks after birth over several matings for
differences in mean pup weights. Pups from -lactalbu-
min–immunized mothers consistently showed a failure to
thrive as measured by significantly decreased mean pup
weights over several mating cycles (P  0.04 for every
esponse. A: Western blot analysis to detect His-tagged mouse -lactalbumin.
molecular weight markers are indicated on the left side of the gel. B: SWXJ
CFA. Ten days later, LNCs showed antigen-specific proliferation in recall
n cochlin, an irrelevant control antigen cloned and purified in an identical
g/mL of -lactalbumin showed production of the type 1 proinflammatory
L-5 and IL-10. D: Recall responses to 20 g/mL of -lactalbumin were elicited
ays after immunization with -lactalbumin. Data are given as mean  SE.mune r
tions of
umin in
t huma
ith 20 individual mating; Figure 4A). The decreased mean indi-
pt for t
re given
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fertility since there were no significant differences (P 
0.60) in the mean number of mice per litter between
females immunized with -lactalbumin and those immu-
nized with CFA alone (Figure 4B). The observed nourish-
ment failure often presented with pups showing alopecia
(Figure 4C) and liver toxicity (Figure 4D) consistent with
kwashiorkor, a severe nutritional deficiency often observed
in children during famine.26 Severe runting occurred only
in pups from mothers immunized with -lactalbumin and
never occurred in pups from control-immunized mice. In
addition, severe irritation of the nipples occurred only in
-lactalbumin–immunized nursing mice, indicating deter-
mined efforts by the pups to obtain needed nourishment
(data not shown). This breast failure phenotype mimics
that observed in -lactalbumin–deficient transgenic
mice27 and in epidermal growth factor receptor 2
(HER2)–deficient transgenic mice immunized with xeno-
geneic HER2 DNA.28
Passive Transfer of Autoimmune Breast Failure
with Primed T Cells
We next determined whether autoimmune-induced
breast failure was mediated by T or B cells. To this end,
we transferred defined lymphocyte populations and sera
from -lactalbumin–immunized mice into naive recipients
and found that the pup growth inhibition phenotype could
be transferred into lactating recipients with -lactalbumin–
Figure 3. Altered gene expression in lactating breast tissues from -lactalbum
alone, total RNA from lactating mammary tissue was analyzed for gene expres
mice showed significantly elevated gene expression levels of IFN- (P 
-lactalbumin (P  0.002) and -casein (P  0.0008). Asterisks indicate sig
in nonlactating breast tissue from -lactalbumin–immunized mice. C: Exce
examined from normal nonlactating -lactalbumin–immunized mice. Data aactivated LNCs (P  0.04) but not with -lactalbumin–primed B cells (P  0.50) or sera (P  0.60) (Figure 5A).
Moreover, we found that significantly elevated -casein
gene expression, a surrogate marker for autoimmune
breast failure (Figure 3A), did not occur in lactating
breast tissues from control females receiving cochlin-
primed and activated LNCs (P  0.10) but did occur in
lactating breast tissues from females receiving -lactal-
bumin–primed LNCs (P 0.02), CD4 T cells (P 0.03),
or CD8 T cells (P  0.02) (Figure 5B). Taken together,
these results indicate that autoimmune-induced breast
failure is mediated by -lactalbumin–specific CD4 or
CD8 T cells and not by B cells or antibody.
Discussion
In the present study, we developed and characterized a
novel mouse model for autoimmune breast failure. Immu-
nization against the breast-specific lactation protein
-lactalbumin causes T-cell–mediated mastitis in lactat-
ing mice. The targeted breast-specific inflammation
causes functional failure of the breast characterized by
lactation insufficiency, resulting in decreased ability to
nurture offspring. Pups nursed by -lactalbumin–immu-
nized mice show significantly delayed growth often ac-
companied by kwashiorkor-like nutritional abnormalities,
including alopecia, liver toxicity, and runting.
It is important to note that nonlactating mice immu-
nized with -lactalbumin were completely unaffected by
inflammatory signs associated with the breast failure phe-
unized mice. Six weeks after immunization with either -lactalbumin or CFA
real-time qRT-PCR. A: Lactating breast tissue from -lactalbumin–immunized
but not IL-10 (P  0.10) and significantly increased gene expression of
e. B: -Lactalbumin and -casein gene expression levels were not elevated
he spleen, IFN- gene expression levels were not elevated in any tissues
as mean  SE.in–imm
sion by
0.001)
nificancnotype. They showed no histologic signs of T-cell infil-
s, includ
amic py
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lar indications of any inflammatory mediators in breast
and other tissues. Indeed, the benign nature of -lactal-
bumin immunization in nonlactating mice has formed the
basis for designing a prophylactic breast cancer vac-
cine.29 Vaccination against -lactalbumin provides im-
mune protection against the development of transplant-
able and autochthonous breast tumors in mice without
causing inflammatory complications. Thus, conditionally
expressed self-proteins or self-proteins that are “retired”
and are no longer expressed may substitute for unavail-
able viral targets in the development of a prophylactic
cancer vaccination.30 The present results reevaluate and
confirm the safety of immunization against breast-spe-
cific, conditionally expressed lactation proteins as pro-
phylaxis against breast cancer provided that lactation is
avoided after immunization.
This experimental model of autoimmune breast failure
may have useful applications for addressing inflamma-
tory complications during lactation and the associated
inability to continue breastfeeding. This inflammatory
mastitis manifests in a substantial population of lactating
women usually within the first few weeks of delivery and
often leads to cessation of breastfeeding. It is well estab-
lished that early postnatal nutrition plays an important role
in the long-term health of offspring.31,32 The benefits of
breastfeeding for infants include optimal growth and nu-
Figure 4. Functional phenotype of autoimmune breast failure. Four weeks a
identical males, and the resultant litters were examined daily for differences
showed a failure to thrive as measured by significantly decreased mean pup
indicate significance. B: There were no significant differences (P  0.60) in
CFA alone. Nourishment failure often presented with kwashiorkor-like sign
increased serum glutamic oxaloacetic transaminase (SGOT) and serum gluttrition, enhanced ability to fight infections and avoid al-lergic disorders, and enhancement of maternal-infant
bonding.33 Thus, it is important to encourage and facili-
tate breastfeeding, and this mouse model may be useful
in finding ways to improve the quality and effectiveness of
lactation and breastfeeding.
This experimental model of autoimmune breast failure
also has useful applications for addressing nutritionally
based failure-to-thrive issues, particularly regarding the
long-term implications of postnatal nutritional deprivation.
Nutritional deficiencies at critical periods of infant growth
may induce permanent changes in physiologic function.
Breastfeeding is associated with a reduced incidence of
gastroenteritis and respiratory disorders during infancy33–36
and leads to benefits during adulthood that include re-
duced serum cholesterol concentrations,37–39 reduced
mortality from ischemic heart disease,40 reduced inci-
dence of type 2 diabetes mellitus,41 and Helicobacter
pylori infection associated with gastric ulcer formation.42
Other studies indicate that breastfeeding is also associ-
ated with a reduced prevalence of childhood obesity.43
Malnutrition in childhood has long-term implications, in-
cluding the tendency to develop impaired glucose toler-
ance and pancreatic damage, leading to malnutrition
diabetes.44 However, there is still much more to learn
about the long-term effects of early childhood nutritional
deficiency, particularly regarding long-term defined cog-
unization with either -lactalbumin or CFA alone, females were mated with
pup weight. A: Pups from -lactalbumin–immunized mothers consistently
over several mating cycles (P  0.04 for every individual mating). Asterisks
umber of mice per litter between females immunized with -lactalbumin or
ing alopecia (three pups on the left) (C) and liver toxicity as indicated by
ruvic transaminase (SGPT) levels (D). Data are given as mean  SE.fter imm
in mean
weights
mean nnitive impairment, adult immune dysfunction, and overall
CD4 T
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AJP September 2012, Vol. 181, No. 3longevity, and this autoimmune breast failure model may
facilitate such investigations.45
It is important to note the key observation that immu-
nization with -lactalbumin inhibits mean pup growth
without any significant differences in mean birth weight or
in fertility as measured by the mean number of mice per
litter. This indicates that the observed pathologic abnor-
malities associated with autoimmune breast failure are
exclusively due to postnatal lactation insufficiency, with
no measurable prenatal effect on fertility. Note that during
the four mating cycles examined, none of the female mice
immunized with -lactalbumin showed any clinical signs
other than irritated nipples consistent with determined
attempts by the pups to gain nourishment and deter-
mined efforts by the nursing moms to provide nourish-
ment. None of the -lactalbumin–immunized lactating
mice showed any signs of morbidity, and they seemed
relatively normal in behavior, particularly in terms of their
social interactions and grooming behavior when they
stopped lactating.
Notably, gene expression for -casein and -lactalbumin
was greatly enhanced in breasts undergoing autoimmune
attack. Similar examples of up-regulated gene expression
of tissue-specific differentiation proteins include enhanced
acetylcholine receptor gene expression in patients with my-
Figure 5. Passive transfer of autoimmune breast failure with primed T cel
T cells, B cells, or sera from mice immunized previously with eithe
(approximately 3 to 4 weeks after transfer), mice were euthanized for m
mothers that received B cells (P  0.50; left panel) or sera (P  0.60; m
mothers that received -lactalbumin–activated LNCs (P  0.04; right pa
breast failure, did not occur in lactating breast tissues from control fema
tissues from females receiving -lactalbumin–activated LNCs (P  0.02),
SE. Asterisks indicate significance. In all experiments, n  6.asthenia gravis,46 enhanced ghrelin gene expression injoint tissues of patients with rheumatoid arthritis,47 and
up-regulation of developmental isoforms of myelin pro-
teins in central nervous system tissues during inflamma-
tory stages of autoimmune demyelinating disease.48 This
up-regulated gene expression of tissue-specific differen-
tiation proteins seems to represent a compensatory re-
sponse by the damaged tissue to achieve functional ho-
meostasis. In the case of autoimmune mastitis, the
enhanced gene expression for lactation proteins likely
represents remuneration for the lactation inadequacy in
the autoimmune targeted breast and may have biomarker
potential for determining breast failure.
Finally, this autoimmune mastitis model may serve as a
basis for understanding bovine mastitis, a most prevalent
and costly disease in dairy cows resulting in consider-
able economic loss.49 Although bovine mastitis is often
associated with bacterial infections, antibiotics are not
always successful in alleviating clinical signs in bovine
mastitis, and a substantial number of cases are not as-
sociated with any known pathogen and are diagnosed as
sterile mastitis.50 In addition, the relapsing nature of
bovine mastitis mimics the typical clinical presentation
of autoimmune disease, and the high frequency of
antibiotic-resistant cases of bovine mastitis suggests
that microbial infection may not account for all cases of
ting female SWXJ mice were injected i.p. with LNCs, CD4 T cells, CD8
binant -lactalbumin or recombinant cochlin in CFA. After weaning
r analysis of tissues. A: Inhibition of growth did not occur in pups from
panel) from -lactalbumin–immunized mice but did occur in pups from
: Significantly elevated -casein gene expression, a surrogate marker for
iving cochlin-activated LNCs (P  0.10) but did occur in lactating breast
cells (P  0.03), or CD8 T cells (P  0.02). Data are given as mean ls. Lacta
r recom
olecula
iddle
nel). B
les rece
bovine mastitis. We hypothesize that a cohort of dairy
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AJP September 2012, Vol. 181, No. 3cows with bovine mastitis may actually have an underly-
ing autoimmune etiopathogenic process accounting for
inflammatory signs that may be indistinguishable from
those produced by infection. This hypothesis may be
tested rather easily by examining autoantibody re-
sponses to a broad spectrum of primary milk proteins,
including -lactalbumin and -casein.
In summary, this experimental autoimmune breast fail-
ure model has useful applications for prophylactic breast
cancer vaccination, for addressing inflammatory compli-
cations that prevent breastfeeding, and for investigating
long-term implications of postnatal nutritional deprivation,
and it may be relevant in cases of sterile mastitis in the
dairy industry.
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